Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Casa collettiva per anziani Heiligeist

Progetto di casa per anziani a Potsda

Entwurfe fur Potsdam 1991-2001, Disegni e modelli degli architetti Augusto Romano Burelli e Paola Gennaro

Monografia sui progetti di A.R.Burelli e P.Gennaro a Potsdam, presentati in mostra al Romischen Badern al Park Sanssouci

Chiesa a Gemona, (1988-1996)

Breve presentazione della facciata in pietra della Chiesa di Santa Lucia a Gemona (UD)

La torre-cantina a Gramogliano

Pubblicazione estesa della torre-cantina di Gramogliano, una architettura che sperimenta nuove soluzioni tecnologiche, sia riguardo alla struttura dei solai in legno, sia riguardo alla facciata ventilata in grandi lastre di cotto ricostituito. Una piccola opera di grande suggestione nel paesaggio

IL PROGETTO PER IL CASTELLO DEL PRINCIPE ELETTORE DI HEIDELBERG. In: A.R. BURELLI, Mors et renovatio dell'antico. Il castello di Heidelberg, Il Poligrafo, Padova 2004

PROGETTO PER IL RECUPERO E LA SISTEMAZIONE DEL CASTELLO RINASCIMENTALE DI HEIDELBERG E DELLA PERCORSO DI ACCESSO

Heiligegeistkirche. In: C. Piva, L'evocazione del tipo. L'Heiligegeistkirche a Potsdam.

Presentazione estesa della ricostruzione della Heiligegeistkirche di Potsdam, un progetto di A.R.Burelli e P.S.Gennaro. Disegni e fotografie

HEILIG-GEIST-KIRCHE (Residenz Heilig-Geist-Park)

Progetto e realizzazione della ricostruzione critica della Heiliggeistkirche a Potsdam, 1997-9

PROGETTI BRANDEBURGHESI

CHIESA DELLA TERRA DI NESSUNO, POTSDAM INNENSTADT, MASTERPLAN kKRCHSTEIGFELD, 13 CASE A KIRCHSTEIGFELD, UNTER DEN LINDEN 78, LINDENGALERIE AM KOMISCHEN OPER, HEILIGGEIST PARK A POTSDA